Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets) for HIV prevention
Cabotegravir demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV in clinical trials.
Download (PDF, 173.0KB) -
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia
Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
Download (PDF, 212.1KB) -
GSK and Save the Children renew award-winning partnership, with focus on ‘zero dose’ children who have never received a vaccine
GSK and Save the Children renew their 10-year partnership for a further five years.
Download (PDF, 153.1KB) -
GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator
Submission included data from trials addressing clinical manifestations of myelofibrosis - splenomegaly, constitutional symptoms and anaemia
Download (PDF, 260.8KB) -
GSK’s regulatory submission accepted for review by Japanese regulator for use of Nucala (mepolizumab) in adults with chronic rhinosinusitis with nasal polyps
If approved, Nucala would be first anti-interleukin-5 biologic available in Japan for treatment of adults with CRSwNP
Download (PDF, 191.6KB) -
New Shingrix data demonstrate 100% vaccine efficacy in the prevention of shingles in adults aged 50 and over in China
No cases of shingles (herpes zoster) reported among the participants who received Shingrix in the randomised clinical trial
Download (PDF, 202.6KB) -
New research published in Science highlights potential of a naturally occurring bacterium to help eradicate malaria
GSK scientists have discovered a strain of Delftia tsuruhatensis bacterium, that inhibits P. falciparum malaria parasites in mosquitoes.
-
Jemperli (dostarlimab) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Jemperli is the only immuno-oncology treatment approved in a frontline setting for this patient population in combination with chemotherapy
-
Strong performance and momentum drive upgraded guidance
Q2 2023 performance highlights
-
ViiV Healthcare’s cabotegravir for HIV prevention receives positive CHMP opinion from European Medicines Agency
Cabotegravir is the first and only long-acting injectable option for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1
-
New analysis shows lost ground on adult immunisation during the pandemic with 100 million doses potentially missed
Despite successes in Covid-19 vaccination programmes, global uptake of some other adult vaccines fell during the same timeframe
-
Medicines and Healthcare products Regulatory Agency authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults
Authorisation will help protect adults 60 years of age and older in the UK from RSV disease for the first time
-
GSK completes acquisition of BELLUS Health
BELLUS is a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough.
-
GSK receives US FDA Fast Track designation for investigational vaccine against gonorrhoea
Fast Track designation accelerates the vaccine candidate’s path to US FDA submission for the prevention of Neisseria gonorrhoeae infection
-
Japan’s Ministry of Health, Labour and Welfare approves Shingrix for the prevention of shingles in at-risk adults aged 18 and over
Approval expands the number of people who can be protected against shingles.
-
GSK receives positive CHMP opinion recommending authorisation of daprodustat for symptomatic anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis
The positive CHMP opinion is based on data from three global phase III trials in dialysis patients from the ASCEND clinical trial programme.
-
Statement - Zantac (ranitidine) litigation
GSK today confirmed it has reached a confidential settlement with James Goetz.
-
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend Arexvy for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
Committee recommendations mean over 55 million older adults in the US could have access to RSV vaccination for the first time
-
GSK shares positive data for Arexvy, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
Results from the ongoing AReSVi-006 phase III trial show vaccine efficacy over two full seasons
-
GSK announces extension of FDA review period for momelotinib
GSK is confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review.
